JAMA Dermatology

JAMA Dermatology JAMA Dermatology is a member of the JAMA Network, a consortium of peer-reviewed publications.

In this cross-sectional study, ectropion was evaluated and scored in patients with epidermal differentiation disorders (...
06/10/2026

In this cross-sectional study, ectropion was evaluated and scored in patients with epidermal differentiation disorders (EDD), including lamellar ichthyosis (TGM1-nEDD) and harlequin ichthyosis (ABCA12-nEDD), using the Ectropion Severity Score (ESS).

The ESS demonstrated excellent reliability among six raters and confirmed that ectropion prevalence and severity are highest in TGM1-nEDD and ABCA12-nEDD, with additional high risk observed in PNPLA1 and SPINK5 genotypes.

These findings validate the ESS as a robust tool for assessing ectropion across EDD genotypes and support its use in future clinical monitoring and treatment response studies. https://ja.ma/4x38OsL

This case report describes a woman in her 30s with melanoma arising in association with a BAP1-inactivated melanocytic t...
06/09/2026

This case report describes a woman in her 30s with melanoma arising in association with a BAP1-inactivated melanocytic tumor.

https://ja.ma/4dXOKQX

Intralesional interleukin-2 produced an 81% complete response rate with only mild adverse events in patients with high...
06/09/2026

Intralesional interleukin-2 produced an 81% complete response rate with only mild adverse events in patients with high-risk squamous cell not eligible for .

https://ja.ma/4e7hs0v

A man in his 70s with a history of hypertension, dyslipidemia, chronic obstructive pulmonary disease, and aortoiliac occ...
06/09/2026

A man in his 70s with a history of hypertension, dyslipidemia, chronic obstructive pulmonary disease, and aortoiliac occlusive disease was admitted with a symptomatic impending rupture of a thoracic aortic aneurysm, followed by reticulate erythematous to violaceous macules that appeared on the dorsal and plantar surfaces of both feet.

What is your diagnosis? Take the Clinical Challenge: https://ja.ma/4dWGOON

A woman in her 60s presents with a 3-year history of pulmonary arterial hypertension and 2-month history of worsening dy...
06/08/2026

A woman in her 60s presents with a 3-year history of pulmonary arterial hypertension and 2-month history of worsening dyspnea and progressive abdominal distension. What is your diagnosis? https://ja.ma/43I5KEN

This case report describes well-circumscribed, yellow-brown atrophic plaques on the legs that were rimmed by erythema an...
06/07/2026

This case report describes well-circumscribed, yellow-brown atrophic plaques on the legs that were rimmed by erythema and scale. https://ja.ma/3RVWz0T

This case report describes a woman in her 30s with melanoma arising in association with a BAP1-inactivated melanocytic t...
06/06/2026

This case report describes a woman in her 30s with melanoma arising in association with a BAP1-inactivated melanocytic tumor. https://ja.ma/4e2fajq

📄 This case report describes 2 patients taking osimertinib and amivantamab who developed ecthymalike ulcerations refract...
06/05/2026

📄 This case report describes 2 patients taking osimertinib and amivantamab who developed ecthymalike ulcerations refractory to tetracyclines and topical steroids. https://ja.ma/4eiO2hf

Intralesional interleukin-2 produced an 81% complete response rate with only mild adverse events in patients with high...
06/05/2026

Intralesional interleukin-2 produced an 81% complete response rate with only mild adverse events in patients with high-risk squamous cell not eligible for .

https://ja.ma/4e3iASL

A network meta-analysis evaluated systemic pharmacological treatments for chronic plaque , synthesizing data from 160 r...
06/05/2026

A network meta-analysis evaluated systemic pharmacological treatments for chronic plaque , synthesizing data from 160 randomized clinical trials with more than 57,000 adults.

Biologic therapies targeting interleukin-17 (IL17) and interleukin-23 (IL23) provided the highest likelihood of achieving Psoriasis Area and Severity Index 90 responses within the 8- to 24-week induction phase, compared to other systemic treatments.

Existing oral therapies had lower short-term efficacy but remain important options for patients preferring noninjectable regimens. Rates of serious adverse events were low and comparable to placebo, supporting the short-term safety profile of these agents. https://ja.ma/4dLyR02

Address

330 N Wabash Avenue
Chicago, IL
60611

Telephone

(312) 670-7827

Website

Alerts

Be the first to know and let us send you an email when JAMA Dermatology posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Featured

Share

Category